Fertility and consumer‑genetics startups are moving beyond disease screening to sell polygenic trait predictions for embryos (height, BMI, ADHD risk, IQ points). These products turn statistical adult predictors into consumer‑facing embryo reports that prospective parents can use to choose among IVF embryos.
— If scaled, commercial embryo trait‑scoring will force policy choices on regulation, equity, reproductive commercialization, and whether small probabilistic trait advantages become inherited status goods.
BeauHD
2026.09.29
48% relevant
Tropic’s business model — developing a gene‑edited consumable and winning multi‑country approvals for commercial rollout — parallels how startups commercialize genetic traits; it shows the same market and regulatory dynamics that have driven embryo/trait‑selection markets into public debate.
BeauHD
2026.09.08
80% relevant
The Atlas converts computational variant interpretation from one‑off model runs into a browser query — the same capability embryo‑selection and reproductive‑tech startups already monetize; DeepMind’s dataset plus Google Cloud licensing (and Isomorphic Labs’ commercial access) makes the underlying product that such startups need far cheaper and faster to build.
Steve Hsu
2026.05.07
92% relevant
The episode centers on polygenic embryo screening methods and commercialisable scoring (ImputePGTA and family‑based approaches) — the exact scientific enablers that startups use to offer embryo trait prediction products to IVF customers.
2026.04.04
88% relevant
This is a direct fit: the article profiles a startup (Herasight) selling embryo‑selection products claiming higher IQ and lower disease risk, which maps onto the trend of commercial firms offering polygenic embryo scoring and the attendant scrutiny over claims and impacts.
2026.04.04
100% relevant
The article names Nucleus and Herasight partnering with Genomic Prediction and advertising an IQ predictor worth ~6–9 points and trait outputs (height, eye color, ADHD), showing the concrete market shift.